- Home
- CELC
CELC
Celcuity Inc.
as of 12-12-2025 3:41pm EST
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 3.1B | IPO Year: | 2017 |
| Target Price: | $100.13 | AVG Volume (30 days): | 945.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.58 - $112.64 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CELC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Celcuity Inc. (CELC)
Director
Avg Cost/Share
$105.69
Shares
3,000
Total Value
$317,069.61
Owned After
8,270
Director
Avg Cost/Share
$98.13
Shares
1,100
Total Value
$107,948.39
Owned After
8,270
SEC Form 4
Director
Avg Cost/Share
$100.00
Shares
15,000
Total Value
$1,500,016.50
Owned After
110,000
SEC Form 4
Director
Avg Cost/Share
$96.73
Shares
3,900
Total Value
$377,254.80
Owned After
8,270
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Buller Richard E | CELC | Director | Dec 5, 2025 | Sell | $105.69 | 3,000 | $317,069.61 | 8,270 | |
| Buller Richard E | CELC | Director | Dec 1, 2025 | Sell | $98.13 | 1,100 | $107,948.39 | 8,270 | |
| Dalvey David | CELC | Director | Nov 21, 2025 | Sell | $100.00 | 15,000 | $1,500,016.50 | 110,000 | |
| Buller Richard E | CELC | Director | Nov 20, 2025 | Sell | $96.73 | 3,900 | $377,254.80 | 8,270 |
Compare CELC vs Leading Stocks
See how CELC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CELC Celcuity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.